drugset

drugset / Trial / NCT00937820

Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism

NCT00937820 ↗

Phase 3 Completed 87 enrolled Astellas Pharma Inc

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The study objective is to evaluate the efficacy and safety of oral YM150 for 52 weeks in patients with a history of venous thromboembolism.

Timeline

Start: 2009-06
Primary completion: 2010-12
Completion: 2010-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	darexaban	Small molecule	—	Oral

Indications